Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.
Regulus is also advancing several programs toward clinical development in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners.
Revenue (Q1, 2018)
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (15-May-2018)
Closing share price (15-May-2018)
|USD||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q1, 2018|
|3.8 m||1.9 m||489 k||483 k||204 k||18 k||18 k||18 k|
General and administrative expense
|5.8 m||4.2 m||5.1 m||3.7 m||4.8 m||4 m||7.1 m||3.8 m|
|19.2 m||11 m||16.8 m||18 m||14.6 m||15.8 m||14.3 m||11.8 m|
Operating expense total
|25 m||15.2 m||21.9 m||21.7 m||19.4 m||19.7 m||21.3 m||15.6 m|
|USD||Q3, 2013||Q1, 2014||Q2, 2014||Q3, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017|
|(21 m)||(13 m)||(21.2 m)||(21.1 m)||(19.5 m)||(20 m)|
|1.1 m||2.7 m||3 m||2.6 m||2.7 m||2.4 m||3.4 m||3.6 m||3.5 m||5.7 m||4.5 m||4.9 m|